Delivery Order SPE2DB20D1004-SPE2DB25FNJWE
- Not listed
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product for treating inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $1,860.59, was competitively awarded with no set-aside designation and is scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp will perform the work from its corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and was competitively awarded without set-aside designation. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a biologic medication used to treat inflammatory conditions. This contract, awarded on July 21, 2025, represents a firm fixed-price delivery order with an ultimate completion date of July 22, 2025. The contract carries no set-aside designation and was awarded competitively. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,796.82 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of inflammatory conditions. This firm fixed price delivery order was awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, and represents a non-set-aside competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNJWEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,856.40 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime pharmaceutical supply vehicle enables AmerisourceBergen to deliver a comprehensive range of medications and medical supplies to support military healthcare programs globally, serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems across multiple therapeutic domains through flexible ordering mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/4/25 |